Business Wire

Chef Marcus Samuelsson Invests in Aleph Farms, Plans to Serve Aleph Cuts Cultivated Steaks

7.6.2023 16:14:00 EEST | Business Wire | Press release

Share

Aleph Farms, a cellular agriculture company designing new ways to grow quality animal products, today announced that Chef Marcus Samuelsson is joining the company as an investor, culinary advisor and launch partner. Through much of his rise to fame as the celebrity chef behind 13 restaurants around the world, a New York Times best-selling author and a TV personality, Samuelsson has been using his unique background to elevate diversity in the culinary world. As part of this designation, he will work closely with Aleph Farms as it approaches commercialization of Aleph Cuts, the world’s first cultivated steaks, providing a new take on steak.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005267/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Marcus Samuelsson x Didier Toubia (Credit: Noi Einav)

“Aleph Farms builds partnerships based on shared values. Like us, Chef Marcus believes in making a positive impact on our food systems with creativity, courage, and care,” said Didier Toubia, CEO and Co-Founder of Aleph Farms. “With his vast experience and focus on creating accessible and inclusive cuisine, Marcus’ insights and expertise are perfectly suited for developing and promoting Aleph Cuts to a wider global audience. Additionally, his reputation for celebrating food cultures that embrace high-quality ingredients aligns with our local approach to promoting food security in ways that can deliver broad social, economic and environmental benefits.”

In his role with Aleph Farms, Samuelsson will advise the company in a culinary capacity, including product development and go-to-market strategies. He has also invested in the company. Chef Marcus will work closely with Aleph Farms as it brings Aleph Cuts to Singapore and Israel later this year and to the United States next year, upon receiving regulatory approvals.

“It’s essential that we look for new ways to feed our planet sustainably, which is why I was attracted to the mission of Aleph Farms and being part, both as a chef and as an investor, in bringing delicious, cultivated meat to the table,” said Samuelsson. “Right now, it’s a pioneering movement and one that I think will only grow to be more important and increasingly commonplace in our lives. What once felt futuristic -- like electric cars -- soon becomes familiar. This is a game-changing moment in the industry to invest in the future, and I’m excited to partner with an innovative company like Aleph Farms.”

In his career, Samuelsson has won eight James Beard Foundation awards as a chef, author and TV personality, including for hosting No Passport Required on PBS. He appeared as an Iron Chef on Netflix’s hit Iron Chef: Quest for an Iron Legend. His restaurants worldwide include Red Rooster Harlem (New York City) and Red Rooster Overtown (Miami), MARCUS Montreal, Marcus B&P in Newark, Streetbird at Yankee Stadium, Marcus at Baha Mar Fish + Chop House in the Bahamas, the recently opened Hav & Mar in Chelsea (New York City) and Marcus Bar and Grille in Atlanta. As a committed philanthropist, Samuelsson is co-chair of Careers Through Culinary Arts Program (C-CAP), which helps underserved youth, and he converted Red Rooster Harlem and Red Rooster Overtown into community kitchens during the COVID-19 pandemic in partnership with World Central Kitchen.

Aleph Farms is working closely with regulatory agencies around the world as it prepares for the commercial launch of its first product under the Aleph Cuts brand, the Petit Steak, grown from non-modified cells of a premium Black Angus cow. As with all its products, there is no slaughter involved in production; instead, from a single fertilized egg, Aleph Farms can grow thousands of tons of cultivated meat, serving as part of a just and inclusive transition to sustainable and secure food systems. The company also has a “Whole Animal” approach by which it plans to produce different cuts of steak as well as other products based on animal cells, such as cultivated collagen, through additional proprietary capabilities.

About Aleph Farms

Aleph Farms is an Israel-based cellular agriculture company active in the food technology space. It designs new ways to grow quality animal products that improve sustainability, food security and animal welfare in our food systems. Founded in 2017, the company unveiled the world’s first cultivated thin-cut beef steak in 2018, the world’s first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts, the company will launch its first product, the Petit Steak, grown from non-modified cells of a premium Black Angus cow. For its contributions to climate leadership including a net zero commitment made in 2020, it has received top accolades from the World Economic Forum and the United Nations.

For more information, follow Aleph Cuts on Instagram and Facebook, Aleph Farms on Twitter and LinkedIn, or visit www.aleph-farms.com. Access our press kit here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Natalee Gibson
alephfarms@songuepr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release

Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye